CHNA
Loncar China BioPharma ETF
CHNA
CHNA
Delisted
CHNA was delisted on the 20th of October, 2023.
3 hedge funds and large institutions have $45K invested in Loncar China BioPharma ETF in 2022 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$15.9K |
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $32K | +$15.9K | +806 | +99% |
|
|
BBPWM
2
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $9K | – | – | – |
|
3
Morgan Stanley
New York
| $4K | – | – | – |
|